EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits